IMUX
Price
$0.98
Change
-$0.00 (-0.00%)
Updated
Aug 6 closing price
Capitalization
93.84M
Earnings call today
NTLA
Price
$11.37
Change
-$0.21 (-1.81%)
Updated
Aug 6 closing price
Capitalization
1.18B
Earnings call today
Interact to see
Advertisement

IMUX vs NTLA

Header iconIMUX vs NTLA Comparison
Open Charts IMUX vs NTLABanner chart's image
Immunic
Price$0.98
Change-$0.00 (-0.00%)
Volume$708.38K
Capitalization93.84M
Intellia Therapeutics
Price$11.37
Change-$0.21 (-1.81%)
Volume$3.89M
Capitalization1.18B
IMUX vs NTLA Comparison Chart in %
Loading...
IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMUX vs. NTLA commentary
Aug 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMUX is a Hold and NTLA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 07, 2025
Stock price -- (IMUX: $0.98 vs. NTLA: $11.37)
Brand notoriety: IMUX and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMUX: 42% vs. NTLA: 80%
Market capitalization -- IMUX: $93.84M vs. NTLA: $1.18B
IMUX [@Biotechnology] is valued at $93.84M. NTLA’s [@Biotechnology] market capitalization is $1.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $210.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMUX’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • IMUX’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, both IMUX and NTLA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMUX’s TA Score shows that 5 TA indicator(s) are bullish while NTLA’s TA Score has 3 bullish TA indicator(s).

  • IMUX’s TA Score: 5 bullish, 5 bearish.
  • NTLA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, IMUX is a better buy in the short-term than NTLA.

Price Growth

IMUX (@Biotechnology) experienced а +1.86% price change this week, while NTLA (@Biotechnology) price change was -7.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.54%. For the same industry, the average monthly price growth was +12.42%, and the average quarterly price growth was +13.42%.

Reported Earning Dates

IMUX is expected to report earnings on Aug 07, 2025.

NTLA is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-0.54% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.18B) has a higher market cap than IMUX($93.8M). IMUX YTD gains are higher at: -2.060 vs. NTLA (-2.487). IMUX has higher annual earnings (EBITDA): -100.85M vs. NTLA (-530.8M). NTLA has more cash in the bank: 504M vs. IMUX (14.3M). IMUX has less debt than NTLA: IMUX (975K) vs NTLA (119M). NTLA has higher revenues than IMUX: NTLA (45.6M) vs IMUX (0).
IMUXNTLAIMUX / NTLA
Capitalization93.8M1.18B8%
EBITDA-100.85M-530.8M19%
Gain YTD-2.060-2.48783%
P/E RatioN/AN/A-
Revenue045.6M-
Total Cash14.3M504M3%
Total Debt975K119M1%
FUNDAMENTALS RATINGS
IMUX vs NTLA: Fundamental Ratings
IMUX
NTLA
OUTLOOK RATING
1..100
1570
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
4544
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
3650

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (28) in the Biotechnology industry is in the same range as IMUX (48) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to IMUX’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IMUX (100) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to IMUX’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as IMUX (100) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to IMUX’s over the last 12 months.

NTLA's Price Growth Rating (44) in the Biotechnology industry is in the same range as IMUX (45) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to IMUX’s over the last 12 months.

NTLA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as IMUX (100) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to IMUX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMUXNTLA
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 16 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
85%
Bearish Trend 1 day ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BLYRX36.350.37
+1.03%
American Beacon Man Lg Cp Growth R6
MDFOX7.84N/A
N/A
BlackRock Large Cap Focus Growth Inv A
CVLFX14.65N/A
N/A
Cullen Value C
NLSCX18.51N/A
N/A
Neuberger Berman Long Short C
VTAIX11.20N/A
N/A
Virtus Tactical Allocation I